Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel

  • Sylvie Houtmann
  • Brigitte Schombert
  • Camille Sanson
  • Michel Partiseti
  • G. Andrees BohmeEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1641)


The human Ether-a-go-go Related Gene (hERG) product has been identified as a central ion channel underlying both familial forms of elongated QT interval on the electrocardiogram and drug-induced elongation of the same QT segment. Indeed, reduced function of this potassium channel involved in the repolarization of the cardiac action potential can produce a type of life-threatening cardiac ventricular arrhythmias called Torsades de Pointes (TdP). Therefore, hERG inhibitory activity of newly synthetized molecules is a relevant structure-activity metric for compound prioritization and optimization in medicinal chemistry phases of drug discovery. Electrophysiology remains the gold standard for the functional assessment of ion channel pharmacology. The recent years have witnessed automatization and parallelization of the manual patch-clamp technique, allowing higher throughput screening on recombinant hERG channels. However, the multi-well plate format of automatized patch-clamp does not allow visual detection of potential micro-precipitation of poorly soluble compounds. In this chapter we describe bench procedures for the culture and preparation of hERG-expressing CHO cells for recording on an automated patch-clamp workstation. We also show that the sensitivity of the assay can be improved by adding a surfactant to the extracellular medium.

Key words

Torsade de Pointes Drug-induced QT prolongation Cardiosafety screening Electrophysiology 



The authors would like to thank David Rampe and Terence Appelqvist for their critical review of the manuscript.


  1. 1.
    Roden DM (2016) Predicting drug-induced QT prolongation and torsades de pointes. J Physiol 594:2459–2468CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rampe D, Brown AM (2013) A history of the role of the hERG channel in cardiac risk assessment. J Pharmacol Toxicol Methods 68:136–122CrossRefGoogle Scholar
  3. 3.
    Terstappen GC, Roncarati R, Dunlop J, Peri R (2010) Screening technologies for ion channel drug discovery. Future Med Chem 2:715–730CrossRefPubMedGoogle Scholar
  4. 4.
    Mathes C (2006) QPatch: the past, present and future of automated patch clamp. Expert Opin Ther Targets 10:319–327CrossRefPubMedGoogle Scholar
  5. 5.
    Crumb WJ Jr, Vicente J, Johannesen L, Strauss DG (2016) An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. J Pharmacol Toxicol Meth 81:251–262CrossRefGoogle Scholar
  6. 6.
    Pearlstein R, Vaz R, Rampe D (2003) Understanding the structure-activity relationship of the human Ether-a-go-go-Related Gene cardiac K+ channel. A model for bad behavior. J Med Chem 46:2017–2022CrossRefPubMedGoogle Scholar
  7. 7.
    Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erikson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM (2004) Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 50:93–101CrossRefPubMedGoogle Scholar
  8. 8.
    Snyders DJ, Chaudhary A (1996) High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 49:949–955PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  • Sylvie Houtmann
    • 1
  • Brigitte Schombert
    • 1
  • Camille Sanson
    • 1
  • Michel Partiseti
    • 1
  • G. Andrees Bohme
    • 1
    Email author
  1. 1.Integrated Drug DiscoverySanofi R&DVitry-sur-SeineFrance

Personalised recommendations